Information  X 
Enter a valid email address

Motif Bio PLC Ord 0.01P (MTFB)

Related News

15-Apr-2019 09:30 AM

Motif Bio losses narrow as R&D expenses fall

Antibiotics developer Motif Bio booked an narrower annual loss as it cut R&D spending. Pre-tax losses for the year through December amounted to $14.0m, narrowing from losses of $44.8m on-year. 'Motif Bio had an incredibly productive year in 2018, i
25-Sep-2018 09:30 AM

Broker Forecast - Peel Hunt issues a broker note on Motif Bio Plc Ord 1p

Peel Hunt today reaffirms its buy investment rating on Motif Bio Plc Ord 1p (LON:MTFB) and cut its price target to 95p (from 102p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk...
25-Sep-2018 07:30 AM

Motif Bio losses narrow on lower R&D spend

Antibiotics developer Motif Bio booked a narrowing of first half losses after it cut back on R&D spending. Net losses for the six months through June narrowed to $7.8m, from $29.7m on-year. 'We made tremendous progress during the first half of 2018
21-Aug-2018 09:04 AM

Amphion Innovations cuts holding in Motif Bio to 8.5%

Antibiotics developer Motif Bio noted that Amphion Innovations had sold some of its holding in the company to an institutional investor. Amphion now held 8.51% of the issued share capital of Motif Bio, the company said. According to Amphion's filin
16-Jul-2018 11:50 AM

Broker Forecast - Northland Capital issues a broker note on Motif Bio Plc Ord 1p

Northland Capital today reaffirms its buy investment rating on Motif Bio Plc Ord 1p (LON:MTFB) and set its price target at 116p. Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk...
08-May-2018 11:10 AM

Broker Forecast - Northland Capital issues a broker note on Motif Bio Plc Ord 1p

Northland Capital today reaffirms its buy investment rating on Motif Bio Plc Ord 1p (LON:MTFB) and set its price target at 115p. Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk...
13-Apr-2018 08:00 AM

Broker Forecast - Peel Hunt issues a broker note on Motif Bio Plc Ord 1p

Peel Hunt today reaffirms its buy investment rating on Motif Bio Plc Ord 1p (LON:MTFB) and cut its price target to 102p (from 106p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk...
10-Apr-2018 10:02 AM

Motif Bio losses deepen on higher staff remunerations costs

Antibiotics developer Motif Bio said annual losses deepened, partly due to a rise in staff remuneration costs as it grew its headcount. Pre-tax losses amounted to $44.8m, compared to red ink of $40.3m in 2016. The increase in expenses was primarily due
04-Apr-2018 11:50 AM

Broker Forecast - Peel Hunt issues a broker note on Motif Bio Plc Ord 1p

Peel Hunt today reaffirms its buy investment rating on Motif Bio Plc Ord 1p (LON:MTFB) and set its price target at 106p. Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk...
20-Mar-2018 01:00 PM

Broker Forecast - Peel Hunt issues a broker note on Motif Bio Plc Ord 1p

Peel Hunt today reaffirms its buy investment rating on Motif Bio Plc Ord 1p (LON:MTFB) and cut its price target to 106p (from 107p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk...
02-Feb-2018 03:07 PM

Motif Bio CFO resigns

Motif Bio said chief financial officer Robert Dickey had resigned. A search process for a new CFO had commenced, the company said. Jonathan E. Gold, currently a non-executive director, had agreed to serve in the role on an interim basis. Dickey would
05-Oct-2017 09:00 AM

Broker Forecast - Peel Hunt issues a broker note on Motif Bio Plc Ord 1p

Peel Hunt today initiates coverage of Motif Bio Plc Ord 1p (LON:MTFB) with a buy investment rating and price target of 106p. Story provided by StockMarketWire.com...
29-Sep-2017 07:54 AM

Motif Bio losses increase

Motif Bio reported a net loss for the six months ended 30 June 2017 and 2016 was $29.7m and $14.2m, respectively. BUSINESS UPDATE: - On April 18 2017, we announced positive top-line results from REVIVE-1, a global Phase 3 clinical trial of our investiga
31-Aug-2017 01:30 PM

Motif Bio to present at Rodman & Renshaw conference

Motif Bio has confirmed that the Company will be presenting at the Rodman & Renshaw 19th Annual Global Investment Conference, to be held between the 10th and 12th of September. In addition, David Huang, MD, PhD, Chief Medical Officer of Motif, will deliv
07-Jun-2017 10:50 AM

Broker Forecast - finnCap issues a broker note on Motif Bio Plc Ord 1p

finnCap today reaffirms its buy investment rating on Motif Bio Plc Ord 1p (LON:MTFB) and cut its price target to 100p (from 125p). Story provided by StockMarketWire.com...
04-Apr-2017 08:10 AM

Broker Forecast - finnCap issues a broker note on Motif Bio Plc Ord 1p

finnCap today initiates coverage of Motif Bio Plc Ord 1p (LON:MTFB) with a buy investment rating and price target of 125p. Story provided by StockMarketWire.com...
01-Feb-2017 09:20 AM

Broker Forecast - Beaufort Securities issues a broker note on Motif Bio Plc Ord 1p

Beaufort Securities today reaffirms its speculative buy investment rating on Motif Bio Plc Ord 1p (LON:MTFB) and set its price target at 110p. Story provided by StockMarketWire.com...
14-Dec-2016 12:50 PM

Broker Forecast - Northland Capital issues a broker note on Motif Bio Plc Ord 1p

Northland Capital today reaffirms its buy investment rating on Motif Bio Plc Ord 1p (LON:MTFB) and cut its price target to 90p (from 140p). Story provided by StockMarketWire.com...
17-Aug-2016 11:10 AM

Broker Forecast - Beaufort Securities issues a broker note on Motif Bio Plc Ord 1p

Beaufort Securities today downgrades its investment rating on Motif Bio Plc Ord 1p (LON:MTFB) to hold (from speculative buy). Story provided by StockMarketWire.com...
16-Aug-2016 07:44 AM

Motif Bio widens H1 pretax loss

Motif Bio widens H1 pretax loss of $14.2m, from a loss of $1.9m. It is pleased that lead product iclaprim is in its final stage of development. This followed the the dosing of the first patient with iclaprim in March this year in Motif's two REVIVE
20-Apr-2016 09:40 AM

Motif Bio materially widens FY pretax loss

Motif Bio has materially widened its FY pretax loss to USD8.5m, from a year-earlier loss of USD1.2m. General and administrative expenses rose to USD3.6m, from USD1.1m, while R&D expenses hit USD4.7m, from nil. CEO Graham Lumsden said 2015 was a transform
02-Mar-2016 07:48 AM

MTFB says first patient dosed in iclaprim in Phase 3

Motif Bio confirms the dosing of the first patient in two Phase 3 clinical trials of its lead antibiotic candidate iclaprim, for the treatment of acute bacterial skin and skin structure infections (ABSSSIs). The REVIVE (Randomized Evaluation IntraVenous
07-Dec-2015 01:52 PM

Motif Bio to present at Biotech Showcase

Motif Bio, the clinical stage biopharmaceutical company specialising in developing novel antibiotics, has been selected to present at the Biotech Showcase 2016, San Francisco, on 11 January at 1400 PST; Track: D - Powell (3rd Floor). Biotech Showcase,
27-Aug-2015 09:22 AM

Motif Bio continues development of new antibiotic

Motif Bio (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, has announced its maiden interim financial results as an AIM-listed company. The net loss for the period was $1.86m. Graham Lumsden, CEO of
10-Jul-2015 01:40 PM

Motif Bio resolutions passed

Motif Bio has announced that at the General Meeting held earlier today all resolutions were duly passed. At 1:40pm: (LON:MTFB) Motif Bio Plc Ord 1p share price was 0p at 64p Story provided by StockMarketWire.com...
 
Headlines
Top categories
Company finder

a d v e r t i s e m e n t